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Background: Despite encouraging outcomes in vascularized composite allograft (VCA) transplantation, the risks of
chronic immunosuppression limit widespread applicability. It has been suggested that infusion of donor bone marrow
along with the VCA may reduce the level of immunosuppression required to prevent clinical VCA rejection. However,
no clear evidence has yet been presented to confirm the role of donor bone marrow in the prevention of rejection. In
this study we investigated the immunologic effects of concurrent bone marrow transplantation in a large animal VCA
model. Methods: MGH miniature swine (nD4) received a non-myeloablative conditioning regimen consisting of low-
dose total body irradiation, T-cell depletion, a short course of Cyclosporine A, with or without varying doses of donor
bone marrow cells in combination with a complete MHC-mismatched VCA. Animals were monitored daily for signs of
rejection or graft versus host disease. Chimerism levels were assessed using flow cytometry and in vitro assays were
performed to assess for donor-specific responses. Results: Transient chimerism was prolonged with increased bone
marrow cell doses and total body irradiation. While animals that received BMC infusions did not have significantly
prolonged VCA acceptance following cessation of immunosuppression compared to animals that received conditioning
without BMCs, they demonstrated better early clinical outcomes and demonstrated donor-specific unresponsiveness
during the presence of detectable chimerism. Conclusions: Detectable mixed chimerism following bone marrow
transplantation and VCA mitigates donor-specific responses and acute rejection episodes, but does not appear to be
sufficient for tolerance induction.
Introduction
Vascularized composite allograft (VCA) transplantation
refers to the allogeneic transfer of multiple tissue types,
including skin, muscle, bone, blood vessels and nerves.
Over the past 15 years, the use of VCAs has emerged as a
viable reconstructive option for patients with the most
severe disfigurements. To date, VCAs of the face, upper
extremities, lower extremities, abdominal wall, larynx,
uterus and knee have been performed, with follow-up
reports demonstrating very encouraging outcomes.1-4 Face
transplant recipients have consistently regained sensation
by 8 months and motor function during the first year fol-
lowing the procedure, coinciding with the recovery of
important functions such as eating, smelling, smiling,
speaking, and swallowing.4-6 Similarly with hand transplan-
tation, follow-up data has demonstrated restoration of tac-
tile sensibility in 90% of hand transplant recipients, with
84% developing discriminative sensation.1 Motor recovery
at 9 to 15 months following transplantation has resulted in
improved ability to eat, drive, grasp objects, shave, use the
telephone and write.1,2
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Despite the promising early outcomes in the field of VCA,
acute rejection episodes of the skin are common even when
under robust conventional triple therapy immunosuppres-
sion. The skin is an important immunologic organ- half of all
cells in the skin have an immune function, and the high con-
centration of adhesion molecules within the dermis provides
the ideal platform to mount an immune response.7 Indeed,
the immunogenicity of allografted skin was described by
Gibson and Medawar 70 years ago,8 and it is therefore not
surprising that different tissues within the VCA have differ-
ent antigenicity.9
Therefore, the establishment of tolerance of fully major
histocompatibility complex (MHC)-mismatched VCAs,
where recipients can maintain allografts without the need
for immunosuppression, remains an important goal to
allow more widespread use of VCAs. Unfortunately, while
many protocols have achieved transplant tolerance in
small animal models, these protocols have generally
failed to translate into large animal models or clinical
regimens.10,11
One approach stands in contrast to this record: the estab-
lishment of mixed haematopoietic chimerism through non-
myeloablative conditioning and haematopoietic stem cell
transplantation (HCT), where lymphoid and haematopoietic
cells of both donor and host origin are present in the recipi-
ent.12-18 Mixed chimerism protocols have been used to
induce tolerance in clinical trials of kidney transplanta-
tion.12,19 However, while multilineage chimerism was tran-
sient with no donor cells detectable after day 21, 7/10
patients remained tolerant of their renal allografts without
maintenance immunosuppression. Furthermore, preliminary
work investigating the induction of tolerance of VCAs in por-
cine models using mixed chimerism approaches has sug-
gested that specific tissues within the VCA (e.g. epidermis)
may be more resistant to long-term acceptance depending
on VCA composition, relative MHC- and minor-antigen
matching, source of haematopoietic stem cells, and persis-
tence of chimerism.20,21
These outcomes suggest that similar protocols may be
applicable to VCA, and strategies to eliminate or reduce
the need for immunosuppression have been attempted
using infusion of donor HSCs in combination with VCA.22
While the first recipient of a face transplant received HSCs
on days 4 and 11 post-transplant, acute rejection episodes
still occurred while on conventional triple-therapy immu-
nosuppression.23 In contrast, it has recently been reported
that hand transplant recipients who received infusions of
bone marrow from donors were able to maintain their
allografts on tacrolimus monotherapy, with infrequent
acute rejection episodes that were easily reversed by
either steroid boluses or topical immunosuppression.
While these experiences do not demonstrate the ability to
induce long-term tolerance of VCAs clinically, they do
suggest that inclusion of donor HSCs may provide for a
positive immunomodulatory effect on VCA outcomes, pro-
viding the basis for these studies.
Methods
Animals
The MGH miniature swine model has fixed MHC (SLA)
haplotypes, which has been achieved through a selective
breeding program. Recipient animals (nD4, SLAdd) were cho-
sen to be fully mismatched for both haplotypes of class I and
class II of MHC from donors (SLAcc). Pig Allelic Antigen (PAA),
a non-histocompatibility antigen, was mismatched between
donors (PAA-positive) and recipients (PAA-negative) to allow
monitoring of origin of cell lineages following BMT. The
study was approved by the Institutional Animal Care and
Use Committee and conducted in accordance with the NIH
guide for the Care and Use of Laboratory Animals.
Conditioning regimen
Recipient animals received a conditioning regimen con-
sisting of low-dose total body irradiation (100cGy on day ¡2
or 200cGy divided in 2 100 cGy doses on days ¡3 and ¡2),
T-cell depletion with CD3 immunotoxin (0.05 mg/kg i.v.,
twice daily from day ¡4 to day 0) and oral Cyclosporine A
(Novartis Pharmaceuticals, East Hanover, NJ) for 45 d starting
from day ¡1, which dose adjusted to maintain levels
between 400–800 ng/mL, as previously described.16,24
VCA transplantation
On day 0, SLAdd recipient animals received a fully MHC
mismatched VCA from the SLAcc donor animals and simulta-
neous bone marrow transplantation. A gracilis musculocuta-
neous VCA was raised as previously described25 from the
donor thigh and included skin, subcutaneous tissue, a large
portion of the gracilis muscle and a vascular pedicle includ-
ing the saphenous artery and vein. The VCA was trans-
planted to the cervical region of the recipient animal and re-
anastomosed to the common carotid artery and the internal
jugular vein.
Bone marrow harvest and transplantation
Bone marrow was harvested from the long bones and
vertebrae of donor animals and collected into 500ml sterile
bowls, with all steps performed at room temperature. Bone
marrow cells were isolated in harvest medium consisting
of Dulbecco’s Phosphate-Buffered Saline (Mediatech), 2%
Knock-Out Serum Reducer (KSR; Invitrogen), 1£ PenStrep
(Invitrogen), 20ug/mL Gentamicin (Invitrogen). Large frag-
ments were allowed to settle for 2 minutes prior to collect-
ing released cells. The fragments were twice extracted of
additional cells by brief swirling in harvest medium and
released cells pooled with the initial concentration. Sus-
pended cells were then filtered through 100u nylon mesh
into 500mL conical bottles and centrifuged for 15mins. Cells
were then re-suspended in 500ml Dulbecco’s Phosphate-
Buffered Saline (DPBS), counted and diluted to 500mL with
DPBS prior to infusion. After preparation the haematopoietic
cells were transplanted over 30 minutes at a dose ranging
from 7.8£108 to 4£109 cells/kg of recipient body weight,
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with one animal receiving no cells. The animals were moni-
tored for signs of adverse events following bone marrow
infusion.
Post-operative VCA management
VCA recipients were monitored for signs of rejection or
technical failure hourly for the first 6 hours and twice daily
thereafter. VCAs were assessed for clinical signs of infection,
erythema, epidermolysis or skin induration. VCA biopsies
were performed at weeks 1, 2, 4 and 8 and at additional
time-points if there was clinical suspicion of rejection.
Chimerism monitoring
Chimerism was assessed by flow cytometry twice weekly
during the first week following transplantation and once
weekly thereafter by monitoring the presence of donor
(PAAC) peripheral blood mononuclear cells in the peripheral
blood of the recipient (PAA-). The following cell markers
were used: CD3 (898H2–6–15; mouse IgGaK), CD4 (74–12–4;
mouse IgG2bK), CD8a (76–2–11; mouse IgG2aK), CD172
(74–22–15; mouse IgG1K) and PAA (1038H-10–9; IgMK).
Bone marrow and thymic biopsies were performed prior to
bone marrow transplantation and at days 50 and 100 and
assessed for chimerism by flow cytometry. Chimerism was
defined as the temporary (transient chimerism) or long-term
(persistent chimerism) coexistence of donor-derived and
recipient cells in the host. Tolerance was defined as indefi-
nite persistence of VCA survival assessed by direct observa-
tion, histologically and through in vitro assays. HSC
engraftment was defined as presence of donor-derived
bone marrow colony-forming units (CFU’s) over 14 weeks
following transplantation.
Mixed lymphocyte reaction assays
Mixed lymphocyte reaction (MLR) assays were performed
to assess in vitro lymphocyte responsiveness to self, donor
animals and third-party animals (outbred Yorkshire).
Responder (4 £ 105 cells) and stimulator (4 £ 105 cells, irra-
diated with 25cGy) peripheral blood mononuclear cells
(PBMC) isolated from the blood of animals, were plated
together in 96 well plates and incubated for 5 d at 37C in
5% C02 and 100% humidity. Following this, responder cells
were pulsed with H3 thymidine and incubated further for
5 hours. Proliferation of responder cells was assessed by the
uptake of the H3 thymidine.
Results
Transient chimerism is prolonged with increased bone
marrow transplantation doses and total body irradiation
In this study, 4 SLAdd recipients were conditioned using a
protocol that includes T cell depletion (using CD3 immuno-
toxin), total body irradiation at either 100 (nD2) or 200
(nD2) cGy, and a 45 day course of Cyclosporine A (target
daily range 400–800ng/mL over days 0–30, tapered to 0 by
day 45). Recipients received fully MHC-mismatched bone
marrow cells (BMCs) at one of 3 doses: 7.1£108, 1.4£109, or
4.0£109 cells/kg, with one control animal not receiving any
cells, and a gracilis myocutaneous VCA from the BMC donor
was performed on day 0 of the protocol for all animals
(Table 1).
Animals that received 100cGy TBI with either 7.1£108 or
1.4£109 cells/kg (animals 19599 and 19839) had minimal
levels of myeloid chimerism (<5 % in both monocyte and
granulocyte lineages) detectable within the first 2 weeks
and no detectable donor-derived lymphocytes at any time
(data not shown). Prolonged and higher levels of chimerism
were observed in animal 20198, who received 200cGy TBI
and the highest amount of bone marrow cells (4.0£109
cells/kg), with donor-derived granulocytes (43.35%) and
monocytes (35.30%) peaking on day 30 post-BMT (Fig. 1).
Similar to the other BMC recipients, only a few donor lym-
phocytes were detected 4 d following BMT but not at any
later time points, suggesting that donor-derived thymopoie-
sis was not established. In this recipient, chimerism levels
decreased quickly and no donor cells were detectable by
flow cytometry after day 60, coinciding with cessation of
Cyclosporine A on day 45. In the animal that received condi-
tioning without bone marrow transplantation (20011), no
donor-derived cells were detected at any time point as
expected (data not shown). For all 3 recipients of bone mar-
row transplantation, PCR analysis of DNA isolated from bone
marrow colony forming units, on day 50 and day 100, for
donor class Ic was not detected, indicating that long-term
engraftment of donor haematopoietic stem cells did not
occur (data not shown).
Transient chimerism modulates early clinical VCA
progression but does not prolong VCA acceptance
following cessation of immunosuppression
In the control animal (20011) that received conditioning
without BMCs, the presence of skin changes started on day
Table 1. Summary of experimental findings
Animal No.
Haplotype
mismatch
Total Body
Irradiation (TBI)
CyA
(days)
Mixed Chimerism/
Engraftment
Bone Marrow
dose
Skin Rejection
crises
Muscle Survival
(days)
Skin survival
(days)
19599 CC!DD 100 CGy 45 No / No 7.1 £ 10^8 cells/kg Day 8–13 62 49
19839 CC!DD 100 CGy 45 No / No 1.4 £ 10^9 cells/kg Day 5–8 53 46
20198 CC!DD 200 CGy 45 Yes/No 4 £ 10^9 cells/kg No 73 62
20011 CC!DD 200 CGy 45 No / No No Day 14–45 15 61
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15 with erythema (Fig. 2), and VCA rejection was complete
by day 77, with hyperkeratosis and sloughing seen in the
overlying skin epidermis. Histological analysis of biopsies
confirmed muscle cellular rejection as early as day 15, with
perivascular mononuclear cell infiltrate in the dermis and
partial degeneration and necrotic muscle (Fig. 3).
The two recipients (animals 19599 and 19839) treated
with 100cGy total body irradiation and 7.1£108 or 1.4£109
cells/kg displayed similar outcomes for VCA survival to the
control animal (Table 1), and both had early acute rejection
crises, starting around day 5 but underwent spontaneous
resolution (recipient 19839 shown in Figure 4, recipient
19599 shown in Supplementary Figure A). As Cyclosporine A
was being tapered, VCAs underwent rejection of the skin
component, complete by days 46 (animal 19839) or 49 (ani-
mal 19599), followed by rejection of the muscle, by days 56
or 62, respectively.
In the animal that received with the highest dose of BMCs
(4.0£109 cells/kg), during the time period in which donor
cells were detectable in the peripheral blood, the VCA dis-
played no evidence of rejection (Fig. 5), and histological
examination on day 38 demonstrated viable skin with no
evidence of lymphocytic infiltrate (Fig. 3). But, while no early
skin rejection crises were observed, the VCA was rejected
following cessation of Cyclosporine A, with the skin lost by
day 62 (Fig. 5) and the muscle surviving till day 73.
Bone marrow transplantation induced transient
donor-specific unresponsiveness during the presence of
detectable chimerism
To assess the effect of donor bone marrow cells on the
immune status of VCA recipients, we compared the
responses of PBMC from animals 20011 (who received con-
ditioning with 200cGy TBI and no bone marrow cells) and
20198 (who received conditioning with 200cGy TBI and
4.0£109 cells/kg) to self, donor and third party antigens.
Prior to undergoing the conditioning regimen, both animals
demonstrated significant responses to donor and third party
antigens (Fig. 6). On day 21 post-VCA transplantation, the
recipient of donor bone marrow cells was specifically unre-
sponsive to donor while maintaining third party reactivity,
whereas at a similar time point (day 14), the control animal
still demonstrated responsiveness to donor antigens, illus-
trating that conditioning without bone marrow transplanta-
tion did not confer donor-specific unresponsiveness.
Following rejection of the VCA, animal 20198 regained MLR
responses to donor antigens (Fig. 6), further illustrating that
Figure 1. Flow cytometric analysis of peripheral blood chimerism of
recipient 20198. PAACCD3C (lymphocytes), PAACCD16C (monocytes),
and PAACCD172aC (granulocytes) are expressed as a percent of total,
respectively.
Figure 2. Time course for animal 20011s (higher TBI, no BM cells) VCA rejection. Skin erythema was evident starting on post-transplant day 15. Crusting
and rejection of the epidermis occurred by day 40. Full VCA rejection (skin and muscle component) was complete by day 77.
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the induction of donor-specific non-responsiveness was
transient in nature.
Discussion
While VCA transplantation has gained increasing accep-
tance, with over 100 patients treated with these reconstruc-
tive procedures, the inherent MHC-mismatching requires
lifetime chronic immunosuppression, thus subjecting the
recipient to possible renal failure, infection and malignancy,
as well as significant financial burdens. Additionally, even
when taken as directed, these drugs often do not prevent
patients from developing VCA rejection crises or chronic
rejection.1,4,26-28
In this study, we investigated the effect of infused BMCs
on the outcome of VCA transplantation, comparing animals
that received different conditioning regimens and doses of
bone marrow. In this study, transient mixed chimerism was
observed in the animal receiving the highest dose of BMCs
and TBI, and this coincided with lack of early rejection crises
and a healthy clinical appearance of the VCA while the ani-
mal remained chimeric. Furthermore, early in vitro unrespon-
siveness to the donor was demonstrated in this animal while
chimerism persisted, demonstrating the immunomodulatory
effect of the transient chimerism.
Notably, chimerism levels fell rapidly following cessation
of CyA, and no evidence for engraftment of long-term repo-
pulating stem cells (LTR-SCs) was demonstrated. Signs of
flap rejection were observed soon after the loss of chime-
rism/cessation of CyA in all animals, and the flap was
completely rejected soon after chimerism was no longer
detectable. Following rejection of all components of the
VCA, in vitro responses to donor antigens were again
observed. These results are in contrast to the animal that
received the conditioning without BMT, which displayed a
robust in vitro anti-donor response throughout the course of
treatment. These results suggest that BMCs mitigate donor-
specific responses in the early period following infusion and
may minimize acute rejection episodes for period of time of
detectable mixed chimerism.
While a clinically relevant protocol for induction of per-
manent VCA transplant tolerance was not achieved in this
study, these data may have important implications. The
Figure 3. H&E stain of VCA skin from animal 20011 (higher TBI, no bone
marrow cells) on day 15 demonstrating focal perivascular mononuclear
cell infiltrate in the dermis (top, left) and partial muscle necrosis and neu-
ral degeneration (top, right). In contrast VCA skin from animal 20198
(higher TBI, highest BM dose) on day 38 showed minimal mixed lympho-
histiocytic inflammation in the skin (bottom, left) and fascia (bottom,
right).
Figure 4. Time course of VCA rejection: animal 19839. An acute rejection crisis of the skin occurred from days 5–8. The VCA appeared healthy until day
40. The overlying VCA skin was rejected by day 46, with the muscle component rejecting by day 56.
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occurrence of acute rejection episodes in clinical recipients
of VCA is consistent with our findings, and provide for justifi-
able rationale for inclusion of donor BMCs as part of the
overall VCA protocol given the ability to mitigate early acute
rejection episodes. Furthermore, while this study does not
address the effect of BMC infusion on the long-term survival
of VCA under the cover of immunosuppression, the
ability to move hand transplant patients onto maintenance
immunosuppression monotherapy when BMCs were
administered22 suggests a positive impact that may have
long-term benefits as well.
Currently, the clinical outcome for VCA acceptance when
HSCs are included in the regimen have differed than the
results observed in the renal transplant protocols,12,19 sug-
gesting a possible difference in the either the ability to
achieve tolerance of a kidney vs. a VCA or the ability of the
organ to contribute to the mechanisms of tolerance. It is
also possible that in contrast to the kidney recipients, recent
VCA recipients did not undergo any conditioning regimen
to facilitate the survival or engraftment of the donor HSCs,
and thus the duration of the transient chimerism was
markedly reduced to the point where donor cells were
undetectable in the blood at any time point. However, in all
3 of the animals presented in this study that received both
conditioning and BMCs, time of VCA rejection was compara-
ble to the animal that received conditioning alone, suggest-
ing the prolonged transient chimerism observed
(presumably through recipient T cell depletion and whole
body irradiation) was insufficient in establishing long-term
tolerance mechanisms able to prolong VCA survival.
Another possible contributing factor that remains to be
explored is the contribution of MHC-matching between
donor and recipient, as in the com-
bined kidney/HSC patients, the toler-
ance was achieved across a single-
haplotype from a living-related
donor. Finally, tolerance may require
more robust approaches for estab-
lishing and maintaining tolerance of
VCAs, as has recently been described
through the induction of stable
mixed chimerism and the indefinite
acceptance of all VCA components,
including skin, across MHC I and II
barriers.29
In conclusion, this study provides
evidence that infusion of donor
BMCs and the establishment of tran-
sient mixed chimerism may reduce
rejection crises in a VCA setting
across a full MHC mismatch, but does
not induce long-term tolerance of a
Figure 5. Time course of VCA rejection: animal 20198. Skin erythema and hyperkeratosis started on day 51. Keratosis increased progressively and skin
necrosis occurred around day 57. VCA was fully rejected by day 62. Both skin and muscle components of the flap were completely rejected by day 73.
Figure 6.Mixed lymphocyte reaction (MLR) assays. Responsiveness against self, donor and third party
was assessed at different time-points following BMT and VCA transplantation. Donor-specific unre-
sponsiveness occurred in animal 20198 while transient mixed chimerism was present (left panel)
whereas animal 20011 demonstrated responses to donor antigens at all time points tested (right
panel). Data is expressed for each stimulator as stimulation index (SI) with standard deviation.
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VCA. This suggests that establishment of long-term, stable
chimerism or the induction of more effective, long-term
immunomodulatory mechanisms will be necessary to pre-
vent rejection of all components of a VCA.
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